- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: July 2026
Elexacaftor with tezacaftor and with ivacaftor, and ivacaftor – July 2026
Public Summary Documents
Last updated
13 November 2026
